SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial.

Bowcock, S; Atkin, C; Iqbal, G; Pratt, G; Yong, K; Neal, RD; Planche, T; Karunanithi, K; Jenkins, S; Stern, S; et al. Bowcock, S; Atkin, C; Iqbal, G; Pratt, G; Yong, K; Neal, RD; Planche, T; Karunanithi, K; Jenkins, S; Stern, S; Arnott, S; Toth, P; Wandroo, F; Dunn, J; Drayson, MT; TEAMM Trial Management Group and Trial Investigators (2023) Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial. Cancers (Basel), 15 (13). p. 3337. ISSN 2072-6694 https://doi.org/10.3390/cancers15133337
SGUL Authors: Planche, Timothy David

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (330kB) | Preview
[img] Archive (ZIP) (Supplementary Material) Published Version
Available under License Creative Commons Attribution.

Download (52kB)

Abstract

Multiple myeloma (MM) patients risk diagnostic delays and irreversible organ damage. In those with newly diagnosed myeloma, we explored the presenting symptoms to identify early signals of MM and their relationships to organ damage. The symptoms were recorded in patients' own words at diagnosis and included diagnostic time intervals. Those seen by a haematologist >6 months prior to MM diagnosis were classified as precursor disease (PD). Most (962/977) patients provided data. Back pain (38%), other pain (31%) and systemic symptoms (28%) predominated. Patients rarely complain of 'bone pain', simply 'pain'. Vertebral fractures are under-recognised as pathological and are the predominant irreversible organ damage (27% of patients), impacting the performance status (PS) and associated with back pain (odds ratio (OR) 6.14 [CI 4.47-8.44]), bone disease (OR 3.71 [CI 1.88-7.32]) and age >65 years (OR 1.58 [CI 1.15-2.17]). Renal failure is less frequent and associated with gastrointestinal symptoms (OR 2.23 [CI1.28-3.91]), age >65 years (OR 2.14 [CI1.28-3.91]) and absence of back pain (OR 0.44 [CI 0.29-0.67]). Patients with known PD (n = 149) had fewer vertebral fractures (p = 0.001), fewer adverse features (p = 0.001), less decline in PS (p = 0.001) and a lower stage (p = 0.04) than 813 with de novo MM. Our data suggest subgroups suitable for trials of 'symptom-directed' screening: those with back pain, unexplained pain, a general decline in health or low-impact vertebral compression fractures.

Item Type: Article
Additional Information: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Keywords: MGUS, diagnosis, diagnostic delay, multiple myeloma, organ damage, precursor disorder, screening, smouldering myeloma, symptoms, TEAMM Trial Management Group and Trial Investigators, multiple myeloma, symptoms, organ damage, screening, precursor disorder, MGUS, smouldering myeloma, diagnosis, diagnostic delay, 1112 Oncology and Carcinogenesis
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Cancers (Basel)
ISSN: 2072-6694
Language: eng
Dates:
DateEvent
25 June 2023Published
9 June 2023Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
08/116/69National Institute for Health Researchhttp://dx.doi.org/10.13039/501100000272
MUK2021.ED03Myeloma UKhttp://dx.doi.org/10.13039/501100004636
PubMed ID: 37444449
Web of Science ID: WOS:001030078100001
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/115757
Publisher's version: https://doi.org/10.3390/cancers15133337

Actions (login required)

Edit Item Edit Item